Specific Inhibition of Allergic Reactions to Penicillin in Man by a Monovalent Hapten

Publisher Website
Google Scholar
Abstract
The monovalent hapten BPO-FLYS has been shown experimentally to inhibit specifically immunological reactions to penicillin in vitro and in vivo. In order to evaluate its potential under clinical conditions, it was administered parenterally to 15 patients having presented acute allergic reactions to penicillin and requesting further penicillin therapy. The parenteral administration of BPO-FLYS (100–400 mg/day) was well tolerated in all cases. An objective demonstration of the inhibiting activity of the hapten, namely, the suppression of previously positive skin tests and a marked diminution of the titer of hemagglutinating antibodies was obtained in most cases. 12 out of 13 patients where it was attempted were able to pursue penicillin therapy without allergic symptoms under cover of the hapten. The demonstration that a monovalent hapten is capable of inhibition specifically clinical allergic reactions to penicillin in man could represent a significant advance in the prevention of penicillin allergy.

This publication has 0 references indexed in Scilit: